PTGDR-1 and/or PTGDR-2 antagonists for preventing and/or treating systemic lupus erythematosus
US11559513B2 · kind B2 · utility
0Cited by
0References
14Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 13, 2020 |
| Grant date | Jan 24, 2023 |
| Priority date | — |
| Expiry date | Apr 13, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2300/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention concerns a PTGDR-1 antagonist, a PTGDR-2 antagonist, a dual PTGDR-1/PTGDR-1 antagonist, or a combination of PTGDR-1 antagonist and PTGDR-2 antagonist, and pharmaceutical compositions containing them, for use for preventing and/or treating SLE.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.